Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Abstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] matched to “Evaluation of HIF-1 inhibitors as anticancer agents” (2007) source
- Partly supportedcites [7] matched to “The role of hypoxia-inducible factors in tumorigenesis” (2008) sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] matched to “Anti-tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors.” (1993) source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a heterodimeric protein that is composed of O2regulated HIF-1 and constitutively expressed HIF-1 subunits (8, 9).”
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“VHL loss-of-function results in constitutive expression of HIF-1 in the majority of clear cell renal carcinomas (11).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Whereas VHL loss-of-function leading to dysregulated HIF-1 expression is restricted to renal cell carcinoma and cerebellar hemangioblastoma, many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Items 501–600 of 620
Boticario, C. B., & Angosto, M. C. (2010) · Anales de la Real Academia Nacional de Farmacia · Cited by 11
Calderón‐Montaño, J. M., Burgos‐Morón, E., & López‐Lázaro, M. (2013) · Deposito de Investigacion Universidad de Sevilla (University of Seville) · Cited by 5
Hypoxia inducible factor one alpha and human viral pathogens
Morinet, F., Parent, M., Pillet, S., Koken, M. H. M., Lebbé, C., & Capron, C. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.11.002 · Cited by 5
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer
Cheng, F., He, J., & Yang, J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.03.007 · Cited by 4
Carlos, A. C. A. M., Lemos, J. V. M., Borges, M. M. F., et al. (2023) · Journal of Applied Oral Science · doi:10.1590/1678-7757-2023-0230 · Cited by 4
Kumar, P. P., Smith, D., Key, J., Dong, H., Ganapathysamy, A., Maranda, V., Wong, N. K. Y., Llauradó, M., Kim, H. H., Zhang, G., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.06.029 · Cited by 4
Liu, H., Huang, C., Liu, Z., Li, Y., Zhu, Y., Gao, M., Chen, J., Zhang, H., Xiao, Z., & Zhao, W. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17405 · Cited by 4
“CGs also modulate the activity of multiple genes, such as HIF1A (H. Zhang et al., 2008), pyruvate kinase PKM2 (Ouyang et al., 2018) and NRF2 (Zhou et al., 2019), leading to the regulation of cellular processes associated with tumour growth.”
Self-citationKarimnia, N., Wilson, A. L., Doran, B. R., Do, J., Matthews, A., Ho, G., Plebanski, M., Jobling, T. W., Stephens, A. N., & Bilandzic, M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404117 · Cited by 7
New Horizons in Cancer Therapy: Manipulating Tumour Metabolism.
Yeluri, S., Madhok, B., & Jayne, D. G. (2012) · Cited by 4
Ouédraogo, G. G., Moukha, S., Mobio, T. A., et al. (2014) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2014.40401 · Cited by 4
“It has been established that cardiotonic steroid glycosides (bufalin and digoxin, for instance) are capable to kill cancer cells through the activation of apoptotic pathways (McConkey et al., 2000; Kurosawa et al., 2001, Zhang et al., 2008).”
BackgroundA phenanthroindolizidine glycoside with HIF-1 inhibitory activity from Tylophora atrofolliculata
Chen, C., Zhu, G., Xie, T.-G., Jiang, P.-C., Wang, J., & Jiang, Z. (2019) · Phytochemistry Letters · doi:10.1016/j.phytol.2019.03.003 · Cited by 4
2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α
Cheng, J., Hu, L., Yang, Z., Suo, C., Wang, Y. J., Gao, P., Cui, C., & Sun, L. (2019) · Cells · doi:10.3390/cells8050439 · Cited by 6
“The levels of mRNAs encoding Bnip3 and HK1 decreased dose-dependently in ALM-treated cells, under both normoxia and hypoxia in Hep3B and PC3 cells (Figure 1B,C).”
BackgroundSelf-citationCirculating levels of hydroxylated bradykinin function as an indicator of tissue HIF-1α expression
Liu, Y., Gu, Y., Ng, S., Deng, Z., Lyon, C. J., Koay, E. J., Ning, B., Katz, M. H. G., Chiao, P. J., Fan, J., et al. (2020) · 中国科学通报:英文版 · doi:10.1016/j.scib.2020.04.023 · Cited by 6
Anticancer and Antiviral Activity of the Pyridine-Biphenyl Glycoside System
Khodair, A. I., Attia, A. M. E., Gendy, E. A., Elshaier, Y. A. M. M., & El‐Magd, M. A. (2020) · Journal of Clinical Haematology · doi:10.33696/haematology.1.020 · Cited by 4
“These compounds containing glycoside bond have been played a vital role as established cancer chemotherapeutic agents [14-27].”
BackgroundLu, H., Zhu, Y., Liu, W., Yan, Y., Jiang, X., Wang, Q., Zhao, Y., He, M., & Wei, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220829095334 · Cited by 6
Hypoxic Pulmonary Vasoconstriction and Chronic Lung Disease
Swenson, E. R. (2013) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-12.3.135 · Cited by 5
“Further supporting pharmacological evidence for HIF-1 alpha mediation of HPV was demonstrated in mice by reduction in hypoxic PH(95) with digoxin, a known inhibitor of HIF-1 alpha transcriptional activity.(96) At present it is not fully clear how HIFdependent gene transcription affects HPV, but it likely involves upre…”
HIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“In vivo , digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
The hypoxic tumor microenvironment: Functional and metabolic reprogramming of key immune populations
Ojaroodi, A. F., Shokravi, S., Eskandarzadeh, S., Ghahremanzadeh, A., Alizadeh, F., Amirikar, F., Mobayen, G., Mahrooghi, D., Lahouty, M., Shamsasenjan, K., et al. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156443 · Cited by 8
Hypoxia-induced NOS1 as a therapeutic target in hypercholesterolemia-related colorectal cancer
Qiu, W., Zhao, L., Liu, H., Xu, P. A., & Qian, C. (2024) · Cancer & Metabolism · doi:10.1186/s40170-024-00338-2 · Cited by 5
Kaewpaeng, N., Wongwan, S., Pansooksan, K., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41963 · Cited by 3
“They play an important role for anticancer activity of the plant [14].”
Signaling Pathways Underlying Bone Metastasis: Hypoxia Signaling in Bone Metastasis and Beyond
Devignes, C.-S., Aslan, Y., & Provot, S. (2018) · Current Molecular Biology Reports · doi:10.1007/s40610-018-0090-1 · Cited by 4
Shahin, H., El‐Hela, A. A., Nasr, M. I., & Nasr, G. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702045 · Cited by 3
“Anticancer and epigenetic effects of this compound have been investigated against various cell lines, such as human lymphoma [5], breast cancer [6,7], human fibroblasts [7], multiple myeloma [8], Embryonal rhabdomyosarcoma [9], prostate cancer [10], and advanced adrenocortical carcinoma [11].”
BackgroundThe Role of Intra-Tumor Hypoxia in Cancer Cells Immune Escape Mechanism
Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_61-1 · Cited by 4
El‐Mahdy, N. A., Tadros, M. G., El-Masry, T. A., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1445708 · Cited by 3
Mechanisms mediating effects of cardiotonic steroids in mammalian blood cells
Poluektov, Y. M., Lopina, O. D., Strelkova, M. A., Kuleshova, I. D., Makarov, A. А., & Petrushanko, I. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1520927 · Cited by 4
Role of Hypoxia-Inducible Factor (HIF) in the Initiation of Cancer and Its Therapeutic Inhibitors
Eda, S. R., Vadde, R., & Jinka, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_10 · Cited by 3
Metabolic reprogramming and tumor immunity under hypoxic microenvironment
Yan, R., Sun, L., & Zhang, H. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2019.01.001 · Cited by 3
Self-citationVascular Smooth Muscle as an Oxygen Sensor: Role of Elevation of the [Na+]i/[K+]i
Orlov, S. N., Birulina, Y. G., Смаглий, Л. В., & Gusakova, S. V. (2017) · InTech eBooks · doi:10.5772/65384 · Cited by 2
“As demonstrated in other cell types [65, 66], hypoxia slightly enhanced Hif‐1a mRNA (Figure 4) but increased immunoreactive HIF‐1α protein content by ~fivefold (Figure 5).”
BackgroundHIF-1α Inhibitors for the Treatment of Posterior Segment Ocular Diseases
Sj, K. (2017) · International Journal of Nanomedicine and Nanosurgery · doi:10.16966/2470-3206.120 · Cited by 3
“It has recently been reported that digoxin has the ability to inhibit HIF-1α protein synthesis [25].”
BackgroundMaggiorini, M., Bärtsch, P., & Swenson, E. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8772-2_5 · Cited by 3
Simulated hypoxia modulates P2X7 receptor function in mice peritoneal macrophages
Faria, R. X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109062 · Cited by 3
Hypoxia and Breast Cancer Metastasis
Schito, L., & Semenza, G. L. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_1 · Cited by 5
“2007) revealed that digoxin and other cardiac glycosides inhibited HIF-1α (and HIF-2α) protein expression and growth of prostate cancer cell xenografts (Zhang et al. 2008).”
BackgroundSelf-citationShifting paradigms for ischaemic preconditioning: AUTHOR'S RETROSPECTIVE
Semenza, G. L. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs197 · Cited by 3
Self-citationZika virus infection induces synthesis of Digoxin in glioblastoma cellsPreprint
Lima, E. D. O., Guerreiro, T. M., Melo, C. F. O. R., de Oliveira, D. N., Machado, D., Lancelloti, M., & Catharino, R. R. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/174441 · Cited by 3
Samanta, D., Gilkes, D. M., Xiang, L., Chaturvedi, P., & Semenza, G. L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497729 · Cited by 5
“Acriflavine binds to HIF-1a and HIF-2a and blocks their dimerization with HIF-1b (26), whereas digoxin blocks the accumulation of HIF-1a and HIF-2a in hypoxic cells (25).”
BackgroundSelf-citationThe Intersection of Pulmonary Vascular Disease and Hypoxia-Inducible Factors
Suresh, M. V., Aggarwal, V., & Raghavendran, K. (2023) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2023.03.010 · Cited by 4
Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs
Sakai, N., Kamimura, K., & Terai, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092190 · Cited by 4
“Further, the study showed that digoxin acts as a hypoxia-inducible factor1 (HIF-1) inhibitor, and its anticancer effect was confirmed in in vivo xenograft models [42].”
BackgroundEghbalifard, N., Nouri, N., Rouzbahani, S., Bakhshi, M., Kahrizsangi, N. G., Golafshan, F., & Abbasi, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-02150-w · Cited by 4
“A tiny chemical called PX-478 prevents HIF-1α from being translated and from being transcribed.”
InfluentialXu, M., Wei, J., Feng, X., Zhang, Q., Chen, J., Wang, X., Zhan, X., Lu, B., Guo, W., Cheng, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202503486 · Cited by 2
Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis
Evans, K., & Seifert, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04443-x · Cited by 2
“Digoxin inhibits protein biosynthesis of HIF1α and expression of its target genes in cancer cells (Wang et al. 2020; Wicks and Semenza 2022; Zhang et al. 2008).”
Molecular Biology of Clear Cell Renal Carcinoma
Kaelin, W. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_2 · Cited by 2
Exploiting “Hif Addiction” For Cancer Therapy
Fer, N. D., & Rapisarda, A. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_14 · Cited by 2
Anti-Convulsants and Gene Expression in Malignant Gliomas
Engh, J. A. (2010) · Neurosurgery · doi:10.1227/01.neu.0000390620.88702.81 · Cited by 2
Ahmed, F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009481107 · Cited by 2
Li, B., Yuan, L., Shi, R.-R., & Wang, J. (2015) · PubMed · Cited by 2
Zhang, B.-X., He, S., Lv, C., Zhang, Y., & Wang, Y. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/6935350 · Cited by 2
Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option
Karimnia, N., Ho, G., Stephens, A. N., & Bilandzic, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98689 · Cited by 2
“The first anti-proliferative effects of CGs were reported more than five decades ago in HeLa cells [137] and since then, multiple studies have highlighted the anti-neoplastic effects of CGs by inducing cancer cell apoptosis [138], activating autophagic cell death through the Ras-dependent extracellular signal-regulate…”
BackgroundRedox Pioneer: Professor Gregg L. Semenza
Prabhakar, N. R. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3155 · Cited by 2
“Whereas conventional wisdom held that hypoxic cells switch to glycolysis as a default state when oxygen levels are limiting for oxidative phosphorylation, Semenza (30) demonstrated that O 2 is not limiting for ATP synthesis when fibroblasts are exposed to 1% O 2 .”
InfluentialReply to Lopez-Lazaro: Evidence that digoxin inhibits human cancer
Zhang, H., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900125106 · Cited by 2
Self-citationComparison of the Effects of Digoxin and Bevacizumab on Oxygen-Induced Retinopathy Rat ModelPreprint
Balbaba, M., Güler, S. D., Ulaş, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1551749/v1 · Cited by 2
Yang, Y., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2022) · doi:10.1101/2022.06.15.492526 · Cited by 2
“Hep3B-c1 cells (10) were treated with the Hopkins Drug Library (20) or vehicle (DMSO), exposed to 20% or 1% O2 for 24 hours, lysed, and the FLuc:RLuc ratio was determined using the Dual Luciferase Assay system (Promega).”
BackgroundMethodInfluentialSelf-citationThe role of Na,K‑ATPase in lung diseases (Review)
Liu, Z., Dong, T., Li, F., et al. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13665 · Cited by 1
“Digoxin has been reported to suppress the expression of HIF1 α , which may provide a more effective therapeutic target for both cancer and SARS‑CoV‑2 infection (76).”
Multi-omics exploration of hypoxia in gastric cancer
Zhu, Y., & Wu, X. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04321-7 · Cited by 1
“Additionally, drugs like Digoxin (a cardiac glycoside) and Acriflavine, which disrupt HIF-1α dimerization, have shown anti-tumor effects in preclinical GC models but lack robust clinical data [42].”
Badawi, G. A., El‐Sayed, R. M., & Fawzy, M. N. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02350-y · Cited by 3
“Digoxin and other cardiac glycosides have been shown to inhibit HIF-1α protein synthesis and have demonstrated efficacy in EAE by selectively suppressing Th17 differen - tiation (Huh et al. 2011; Zhang et al. 2008).”
Tumor hypoxia: Molecular pathways and therapeutic interventions
Li, J., Lin, C.-H., Wang, M.-Y., & Chen, P. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104719 · Cited by 2
Cancer Stem Cells and Glioblastoma Multiforme: Pathophysiological and Clinical Aspects
Soeda, A., Shaffrey, M. E., & Park, D. M. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0809-3_8 · Cited by 1
New Therapeutic Targets in Inflammatory Breast Cancer
Robertson, F. M., & Cristofanilli, M. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0087-3 · Cited by 1
“Given the demonstrated importance of HIF1α as a therapeutic target, and the identification of FDA-approved agents such as the cardiac glycoside digoxin that target HIF1α [51], we are currently investigating HIF1α as a potential therapeutic target for use in clinical trials with IBC patients.”
BackgroundInfluentialDigoxin Effectively Decreased Proliferation of Liver Cancer Cell Line
Tahervand, A., Mahmoudi, M., & Roushandeh, A. M. (2016) · Focus on Sciences · doi:10.20286/focsci-020113 · Cited by 1
“declared that hypoxic conditions inhibit HIF-1α synthesis and exerts its antiproliferative properties in cancer cells [18].”
BackgroundInfluentialNatural Products as Inhibitors of Hypoxia-Inducible Factor-1
Nagle, D. G., & Zhou, Y. (2011) · CRC Press eBooks · doi:10.1201/b11196-8 · Cited by 1
Ouabain inhibits Wnt/β-catenin signaling and induces cytotoxicity in cancer cells
JiaXing, S. O. N. G., Sun, Q., ZhongYuan, W. A. N. G., et al. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00222 · Cited by 1
Hypoxia-Inducible Factor Drives Vascularization of Modularly Assembled Engineered Tissue
Lam, G. C., & Sefton, M. V. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2018.0294 · Cited by 1
Fu, X., & Luo, F. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23487 · Cited by 1
Wang, L. E., & Nakamura, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113883 · Cited by 2
Singh, Y., Jajoriya, A. K., & Kanojiya, S. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100307 · Cited by 1
Transcriptional Regulation of T Cell Metabolism Reprograming
Zhang, J., Bi, G., Xia, Y., Li, P., Deng, X., Wei, Z., & Yang, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_3 · Cited by 3
HIF-опосредованные механизмы взаимосвязи устойчивости к гипоксии и опухолевого роста
Dzhalilova, D. S., & Makarova, O. V. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521100018 · Cited by 1
HIF‐1 Inhibitors for Cancer Therapy
Rapisarda, A., & Melillo, G. (2010) · Wiley eBooks · doi:10.1002/9780470669891.ch17 · Cited by 1
HIF-1α Contributes to the Progression of Chronic Obstructive Pulmonary DiseasePreprint
Zhang, K., Zhou, F., Zhu, C., Yuan, L., Li, D., Wang, J., & Lu, W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.09.472256 · Cited by 1
“activity and thus is often used as a HIF-1α inhibitor (20, 21).”
MethodYuan, G., Peng, Y., Reddy, V. D., Makarenko, V. V., Nanduri, J., Khan, S. A., Garcia, J. A., Kumar, G. K., Semenza, G. L., & Prabhakar, N. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.11.499380 · Cited by 1
“Digoxin inhibits the accumulation of HIF-1α protein (20) and after daily intraperitoneal (IP) injection of digoxin (1 mg/kg) for three days, HIF-1α levels were no longer increased in the CB (Figure 1A) or AM (Figure 1B) of Hif2α+/− mice.”
BackgroundSelf-citationRegulation of Cancer Cell Metabolism by Hypoxia
Pulkoski‐Gross, A., Evensen, N. A., & Cao, J. P. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_4 · Cited by 1
Targeting Hypoxic Adaptations of Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities
Tang, C., & Yu, J. Q. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_14
Fulmer, T. (2009) · Science-Business eXchange · doi:10.1038/scibx.2009.1461
OVERCOMING SELF-REACTIVITY THROUGH IMMUNOLOGICAL AND METABOLIC REDOX MODULATION
Delmastro-Greenwood, M. M. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
HIF-1alpha regulates CD55 expression in airway epithelium
Pandya, P. H. (2015)
Luo, J., Song, T., Cui, F., et al. (2015) · Lecture notes in electrical engineering · doi:10.1007/978-3-662-46318-5_26
Hypoxic Pulmonary Hypertension
Goss, K. N., & Lahm, T. (2015) · Respiratory medicine · doi:10.1007/978-1-4939-2636-7_4
Rilevazione di ossigeno, omeostasi e malattia
Semenza, G. L. (2011)
Self-citationTargeting Could Circumvent Various Chemoresistance
Mijatovic, T., & Robert Kiss, A. (2013)
Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer?
Kalyan, A., & Benson, A. B. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.015883
Lawford‐Smith, H. (2015)
Digoxin and Heart Failure: Are We Clear Yet?
Gupta, A. K., Dakkak, M., & Miller, A. B. (2017) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2016.0044
TARGETING THE HIV-1 LATENT RESERVOIR FOR ERADICATION USING SMALL MOLECULES
Laird, G. M. (2015)
Consequence of Energy Imbalance in Prostate Cancer and Comorbidities
Schenk, J. M., & Wright, J. L. (2017) · Energy balance and cancer · doi:10.1007/978-3-319-64940-5_3
Herzglykoside und ihr Potenzial für die Tumortherapie
Munkert, J., & Kreis, W. (2017) · Deutsche Zeitschrift für Onkologie · doi:10.1055/s-0043-115681
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27558
Комісаренко, С. В., & Романюк, С. И. (2019) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2019.12.003
Lam, G. C. (2018) · TSpace (University of Toronto)
HIF-1α as a Potential Therapeutic Target for Tuberculosis Treatment
Jiang, Q., Gennaro, M. L., & Shi, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-56905-1_4
Targeting glioma stem cell metabolism to enhance therapy responses and minimize resistance
Spina, R., & Bar, E. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822527-1.00007-1
Oxygen Sensing, Homeostasis, and Disease
Bels, D. D., Corazza, F., & Balestra, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1110602
Ca 2+ Mediates HIF-dependent Upregulation of Aquaporin 1 in Pulmonary Arterial Smooth Muscle CellsPreprint
Yun, X., Maman, S. R., Jiang, H., Semenza, G. L., & Shimoda, L. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471473
Self-citationSunami, Y. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_13
Kumavath, R., & Pavithran, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2361555/v1
Treatments for diabetic retinopathy and diabetic macular edema in pipeline
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00011-1
Comparison of the effects of digoxin and bevacizumab on oxygen-induced retinopathy rat model
Balbaba, M., Güler, S. D., Ulaş, F., YILDIRIM, H., Canleblebici, M., & İncili, C. A. (2023) · Journal of Retina-Vitreous · doi:10.37845/ret.vit.2023.32.18 · Cited by 2
Exploring glycolytic adaptations in cancer cells
Matos, B., Howl, J., Jerónimo, C., & Fardilha, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91704-9.00014-8
HIF-1α inhibitor protects against cigarette smoke-induced COPD development in micePreprint
Zhang, K., Zhou, F., Zhu, C., Yuan, L., Li, D., Wang, J., & Lu, W. (2024) · Research Square · doi:10.21203/rs.3.rs-3789467/v1
Marchetti, M., Gros, B. P., Müller, O., et al. (2025) · ASAIO Journal · doi:10.1097/mat.0000000000002473
The Intersection of Pulmonary Vascular Disease and Hypoxia-Inducible Factors
Suresh, M. V., Aggarwal, V., & Raghavendran, K. (2025) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2024.12.014
The Role of Intra-tumor Hypoxia in Cancer Cells Immune Escape Mechanism
Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_61 · Cited by 1
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.